Although the primary objective of reducing the proportion of subjects developing any grade 2 influenza symptom or pyrexia , was not achieved , TCN-032-treated subjects showed 35 % reduction ( P = .047 ) in median total symptom area under the curve ( days 1-7 ) and 2.2 log reduction in median viral load area under the curve ( days 2-7 ) by quantitative polymerase chain reaction ( P = .09 ) compared with placebo-treated subjects .